patientMpower

February 15, 2018February 15, 2018

NICE Opinion Limiting Esbriet to UK Patients with Moderate to Severe IPF Disappoints, patientMpower Says

The digital healthcare company patientMpower expressed disappointment at the opinion issued by an influential U.K. healthcare advisory group to limit the use of Esbriet (pirfenidone, marketed by Genentech) to patients with moderate to ... Read more

January 26, 2018January 26, 2018

Three Winners Will Share $1 Million for Innovation in IPF Catalyst Challenge

Idiopathic Pulmonary Fibrosis, News

Three companies will equally share $1 million for winning the IPF Catalyst Challenge, a competition that fosters innovative solutions for helping idiopathic pulmonary fibrosis (IPF) patients. The winners are Advanced Interactive Response Systems ... Read more

January 24, 2018January 24, 2018

Finalists for $1 million IPF Catalyst Challenge Includes patientMpower

Idiopathic Pulmonary Fibrosis, News

PatientMpower is one of the selected finalists of the IPF Catalyst Challenge to receive $1 million to fund research into idiopathic pulmonary fibrosis (IPF). The IPF Catalyst Challenge, being held ... Read more